Results 41 to 50 of about 140,447 (354)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

CPT: Pharmacometrics & Systems Pharmacology, 2019
Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal ...
Jason Zhang, Kinjal Sanghavi, Jun Shen, Xiaochen Zhao, Yan Feng, Paul Statkevich, Jennifer Sheng, Amit Roy, Li Zhu   +8 more
doaj   +1 more source

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

World Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang   +10 more
doaj   +1 more source

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Frontiers in Pharmacology, 2022
Objective: Nivolumab improves overall survival (OS) and is associated with fewer adverse events than sorafenib for the treatment of advanced hepatocellular carcinoma (aHCC).
Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, Xiaoyu Chen   +5 more
doaj   +1 more source

Biological therapy in the treatment of melanoma [PDF]

, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile, Georgescu, Simona Roxana, Ghita, Ela, Ioghen, Mihaela Roxana, Ion, Alexandra-Florentina, Mitran, Cristina-Iulia, Mitran, Madalina-Irina, Sarbu, Maria Isabela, Tampa, Mircea   +8 more
core   +3 more sources

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2021
PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, M. Butler, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, T. Bas, C. Ritchings, J. Larkin, F. Hodi   +28 more
semanticscholar   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Nivolumab plus ipilimumab in the treatment of advanced melanoma. [PDF]

, 2015
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that
Daud, Adil I, Tsai, Katy K
core   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2019
BACKGROUND In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed ...
M. Hellmann, L. Paz-Ares, R. Bernabé Caro, B. Żurawski, Sang-We Kim, E. Carcereny Costa, Keunchil Park, A. Alexandru, L. Lupinacci, Emmanuel de la Mora Jimenez, H. Sakai, I. Albert, A. Vergnenègre, S. Peters, K. Syrigos, F. Barlesi, M. Reck, H. Borghaei, J. Brahmer, K. O'Byrne, W. Geese, P. Bhagavatheeswaran, S. Rabindran, Ravi S. Kasinathan, F. Nathan, S. Ramalingam   +25 more
semanticscholar   +1 more source

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

New England Journal of Medicine, 2022
BACKGROUND First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal
Y. Doki, J. Ajani, Ken Kato, Jianming Xu, L. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, Chih-Hung Hsu, A. Adenis, F. El hajbi, M. Di Bartolomeo, M. Braghiroli, E. Holtved, S. A. Ostoich, H. R. Kim, Masaki Ueno, Wasat Mansoor, Wen-Chi Yang, Tianshu Liu, J. Bridgewater, T. Makino, I. Xynos, Xuan Liu, M. Lei, K. Kondo, A. Patel, J. Gricar, I. Chau, Y. Kitagawa   +29 more
semanticscholar   +1 more source